#USA #Caris Life Sciences #Liquid Biopsy #Irving #Caris Assure

Caris Life Sciences Unveils Enhanced Liquid Biopsy Technology

On September 29, 2026, Caris Life Sciences®, a prominent name in the AI-focused biotechnology sector, introduced the enhanced Caris Assure®—a significant evolution in the realm of liquid biopsy. This upgraded platform aims to offer more profound molecular insights, which are vital for improving treatment decisions in precision oncology.

The latest Caris Assure integrates multiple advanced techniques, including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and whole-blood analysis, all within a single platform. This comprehensive approach allows clinicians to obtain richer molecular profiles through a mere blood draw, which serves to inform the precision oncology process. Traditional liquid biopsy methods have presented several limitations, and the enhanced Caris Assure seeks to address these issues effectively.

Among the key advancements in the enhanced platform is its ability to differentiate between tumor-derived changes and clonal hematopoiesis as well as incidental germline findings. Caris Assure boasts multiple improvements in analyzing both DNA and RNA, allowing the system to correlate tumor fraction with the risk of cancer progression and treatment effectiveness. This capability is particularly beneficial for patients undergoing repeated testing, as it allows for a categorization of test results into molecular response, intermediate outcomes, or indications of molecular progression.

David B. Spetzler, President of Caris, emphasized the significance of these advancements, stating, “These enhancements represent a pivotal step in our commitment to delivering the most comprehensive molecular information possible.” The enhanced platform offers an extensive genomic coverage exceeding 23,000 genes, with therapy-focused sequencing depth reaching as high as 40,000x. Notably, the RNA sequencing reads have been enhanced to approximately 600 million, enhancing the capabilities for detecting RNA fusion events and expanding biomarker discovery opportunities.

In addition to these scientific improvements, the enhanced Caris Assure introduces a more user-friendly reporting experience, showcasing better visualization of molecular findings and boasting a median turnaround time of around seven days. This streamlined process is designed to enable physicians to access actionable insights quickly, leading to more confident and informed treatment decisions for their patients.

Caris Life Sciences continues to lead the field of comprehensive molecular profiling and remains dedicated to pushing the boundaries of precision oncology through innovative technologies, including large-scale data analytics and AI integration. The introduction of the enhanced Caris Assure not only represents a major advancement in the technology itself but also aims to set new standards for the molecular insights that can be drawn from blood samples, ultimately improving patient care in oncology.

About Caris Assure

Caris Assure is an advanced liquid biopsy platform designed to yield critical molecular insights from blood samples. The enhanced assay combines WES, WTS, and whole-blood analysis, facilitating smarter decision-making in oncology treatments, making it a valuable tool for healthcare professionals.

About Caris Life Sciences

Caris Life Sciences is a leading AI TechBio firm focused on developing innovative solutions to transform healthcare. Through extensive molecular profiling, advanced AI technologies, and large-scale genomic databases, Caris aims to decipher the complex nature of diseases and advance precision medicine.

With headquarters in Irving, Texas, Caris operates additional offices in Phoenix, New York, Cambridge (MA), Tokyo, and Basel, demonstrating a commitment to international service and innovation in healthcare. These advancements underscore Caris’s mission to harness the potential of precision medicine for improving patient outcomes in the fight against cancer.